FDA Awards Priority Review Voucher to Sarepta Therapeutics for Rare Pediatric Disease Product AMONDYS 45

Summary

The FDA has issued a priority review voucher to Sarepta Therapeutics, the manufacturer of AMONDYS 45, a rare pediatric disease product, following a review of the product's eligibility under the FD&C Act and FDASIA.